Sign In
Buy FOLD
$14.49
+0 (+0%)
At Close: Jun 03, 2026
Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
09:26am, Thursday, 09'th May 2024
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.02 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.18 per share a year ago.
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
07:00am, Thursday, 09'th May 2024
1Q 2024 Total Revenue of $110.4M, a 28% Increase Year-over-Year Guiding to Full-Year 2024 Total Revenue Growth of 25%-30% at CER Raising Full-Year 2024 Galafold ® Guidance on Continued Strong Demand
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
07:00am, Wednesday, 08'th May 2024
PRINCETON, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in a fireside chat at the Bank of America 2024 Health Care Confere
Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
11:06am, Wednesday, 01'st May 2024
Amicus Therapeutics (FOLD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
07:00am, Wednesday, 01'st May 2024
PRINCETON, N.J., May 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Thursday, May 9, 2024, at 8:
Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
12:36pm, Friday, 29'th Mar 2024
Amicus Therapeutics (FOLD) reported earnings 30 days ago. What's next for the stock?
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
07:00am, Wednesday, 20'th Mar 2024
PRINCETON, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for r
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
07:00am, Friday, 01'st Mar 2024
PRINCETON, N.J., March 01, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that management will participate in upcoming presentations at the following investor conferences
Amicus' (FOLD) Q4 Earnings Beat, Revenues Meet Estimates
12:26pm, Thursday, 29'th Feb 2024
Amicus' (FOLD) fourth-quarter earnings beat estimates while revenues meet the same. Stock down.
Amicus Therapeutics: Expect Improved Commercial Momentum In 2024
10:05am, Thursday, 29'th Feb 2024
Amicus Therapeutics should deliver strong topline growth with expanding margins and increasing cash flows in 2024.
Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript
01:07pm, Wednesday, 28'th Feb 2024
Amicus Therapeutics, Inc. (FOLD) Q4 2023 Earnings Call Transcript
Amicus Therapeutics (FOLD) Reports Q4 Loss, Lags Revenue Estimates
09:20am, Wednesday, 28'th Feb 2024
Amicus Therapeutics (FOLD) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to loss of $0.19 per share a year ago.
Amicus Therapeutics Announces Full-Year 2023 Financial Results and Corporate Updates
07:00am, Wednesday, 28'th Feb 2024
2023 Total Revenue of $399.4M, a 21% Increase Year-over-Year Strong Patient Demand Continues for Pombiliti ™ + Opfolda ™ in the U.S., U.K., and Germany Projecting 2024 Galafold ® Revenue Growth o
Amicus Therapeutics to Announce Full Year 2023 Financial Results on February 28, 2024
07:00am, Thursday, 15'th Feb 2024
PRINCETON, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Wednesday, February 28, 202
- Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for the Treatment of Late-onset Pompe Disease - - Award Recognizes Approval of Amicus Therapeutics' Two-component Therapy for
